Company News

On 4^th, March 2010, CapitalBio officially joined the Roche NimbelGen Certified Service Provider Program and was certified to provide services including NimbleGen Gene Expression, Comparative Genomic Hybridization/Copy Number Variation (CGH/CNV), and DNA Methylation based on Roche NimbleGen platform. CapitalBio is the first NimbleGen CSP in China to provide such microarray services.

On 27^th Nov, 2009, “Oscar Award” in industrial design, China Red Star Design was given to two CapitalBio’s products, namely SmartArrayer 48 microarray spotter and RT-Cycler Real Time PCR, by China Red Star Design Award Committee.

On 10^th, Dec 2009, CapitalBio passed acceptance check of “Beiochip related instrument commercialization demonstration”, which was audit by a group of experts representing National Development and Reform Commission. Experts also gave very positive feedback on the project success.

On 2^nd Dec, 2009, Cheng Jing, Professor of Department of Biomedical Engineering, Tsinghua University and Chief of Technology in CapitalBio became an academician of the Chinese Academy of Engineering among 48 new academicians, which is top honor life-time achievement in the Chinese Academy of Engineering.

In Nov 2009, CapitalBio was awarded “Innovation Enterprise” by BEEA. Products including LuxScan (confocal laser microarray scanner), CapitalBio Antinuclear Antibody Test Array Kit, CapitalBio Mycobacterial Species Identification Array Kit and CapitalBio M.tuberculosis Drug Resistance Detection Array Kit were awarded “Technology Innovation Product”. CapitalBio foodborne Pathogenic Micro-organisms Detection Array Kit and CapitalBio Deafness Gene Mutation Detection Array Kit were awarded “Technology Innovation Prize”. Dr. Yong Guo was awarded “Technology Innovation Individual”.

Recently CapitalBio Corporation, China’s leading developer of microarray diagnostic products and total analysis solutions announced its Deafness Gene Mutation Detection Array Kit products had received a certificate for diagnostic use from the China State Food and Drug Administration (SFDA).

“International symposium of Deafness and Genetic Medicine” was held jointly by CapitalBio Corporation and 301 Hospital in the main Surgery Building of 301 Hospital on 29^th and 30^th August, 2009.

In August 2009, two new products, namely CapitalBio M.Tuberculosis Drug Resistance Detection Array Kit and CapitalBio Mycobacterial Species Identification Array Kit developed by CapitalBio were accredited as “Beijing Independent Innovation Product” among fifth batch of innovation products. 

On wednesday 29 July, 2009, CapitalBio Corporation and VigeneTech Inc. have announced the launch of a fully integrated microarray solution platform.  CapitalBio Corp., a developer and marketer of diagnostic biochips and advanced microarray instrument systems, in collaboration with VigeneTech Inc., developers of novel image analysis, automation, and instrumentation software, now offer a platform that combines the superior performance and “one-click” automation of the MicroVigene™ image analysis suite with the long established performance of CapitalBio’s LuxScan™ microarray scanners.